<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743129</url>
  </required_header>
  <id_info>
    <org_study_id>2018YJZ47</org_study_id>
    <nct_id>NCT03743129</nct_id>
  </id_info>
  <brief_title>Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）</brief_title>
  <acronym>ALTER-L029</acronym>
  <official_title>A Randomised, Open, Blank-controlled, Multi-centre Study of Anlotinib as Sequential Therapy in Patients With Unresectable NSCLC(Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Shi, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients
      with stage III unresectable non-small cell lung cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug
      Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing
      Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with
      multi-targets, especially for VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β c-Kit and MET.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Estimated to be from baseline up to 3 years</time_frame>
    <description>the time from randomization until the date of objective disease progression (RECIST 1.1) or death (by any cause in the absence of progression)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate at 6 months(DCR6)</measure>
    <time_frame>Estimated to be from baseline up to 3 years</time_frame>
    <description>the percentage of patients with response of Complete Response (CR) or partial response (PR) or stable disease(SD) at least 4 weeks at 6 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate at 12 months(DCR12)</measure>
    <time_frame>Estimated to be from baseline up to 3 years</time_frame>
    <description>the percentage of patients with response of Complete Response (CR) or partial response (PR) or stable disease(SD) at least 4 weeks at 12 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 12 months (OS12)</measure>
    <time_frame>Estimated to be from baseline up to 3 years</time_frame>
    <description>the percentage of patients who are alive at 12 months after randomization per the Kaplan-Meier estimate of overall survival at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 24 months (OS24)</measure>
    <time_frame>Estimated to be from baseline up to 3 years</time_frame>
    <description>the percentage of patients who are alive at 24 months after randomization per the Kaplan-Meier estimate of overall survival at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate at 12 months</measure>
    <time_frame>Estimated to be from baseline up to 3 years</time_frame>
    <description>the percentage of patients with Progressive Disease(PD) at 12 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate at 24 months</measure>
    <time_frame>Estimated to be from baseline up to 3 years</time_frame>
    <description>the percentage of patients with Progressive Disease(PD) at 24 months after randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Non-Small Cell Lung Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib p.o, qd. Treatment from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) to disease progress or untolerated toxicity or consent withdrawal. The 2:1 ratio (Anlotinib to blank).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blank</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) .The 2:1 ratio (Anlotinib to blank).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib 12mg p.o, qd</description>
    <arm_group_label>Anlotinib</arm_group_label>
    <other_name>AL3818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Age at least 18 years.

          -  2.Documented evidence of NSCLC (locally advanced, unresectable, Stage III).

          -  3.Patients must have received at least 2 cycles of platinum-based chemotherapy
             concurrent with radiation therapy.

          -  4.ECOG PS : 0 to 1.

          -  5.Estimated life expectancy of more than 12 weeks.

        Exclusion Criteria:

          -  1.Prior exposure to any anti-angiogenesis drugs.

          -  2.Central lung carcinoma along with large vessels or tumor with cavum or necrosis.

          -  3.Evidence of severe or uncontrolled systemic diseases, including active bleeding
             diatheses or active infections including hepatitis B, C and HIV.

          -  4.Any unresolved toxicity CTCAE &gt;Grade 2 from the prior chemoradiation therapy.

          -  5.Evidence of uncontrolled illness such as symptomatic congestive heart failure,
             uncontrolled hypertension or COPD.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dan Yang</last_name>
    <phone>010-88196984</phone>
    <email>yangdan90117@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Tian</last_name>
      <phone>010-84205380</phone>
      <email>13311163489@163.com</email>
    </contact>
    <investigator>
      <last_name>Guangying zhu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Yang</last_name>
      <phone>010-88196984</phone>
      <email>yangdan90117@sina.com</email>
    </contact>
    <investigator>
      <last_name>Anhui Shi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijuan Jiang</last_name>
      <phone>010-82264913</phone>
      <email>jwjtree@163.com</email>
    </contact>
    <investigator>
      <last_name>Junjie Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunmei Liu</last_name>
      <phone>0311-66003811</phone>
      <email>clclshu@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoying Xue, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 11, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Anhui Shi, MD</investigator_full_name>
    <investigator_title>Associate Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

